Is 2C-I legal in Belgium?

Legal status

2C-I is controlled in Belgium, but not by being named. It is reached by the same generic definition in Annex IVA group 7, applied to the iodinated substitution, and the operative provisions come from the instrument named for this row, the Royal Decree of 6 September 2017, where article 2 defines the controlled substances through Annexes I to V and article 61 routes a breach back to the Law of 24 February 1921. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. Annex IVA is the one part of the list that is open, and it is open only inside the eight precisely printed generic chemical families; a structure that does not fit the printed core and substituent ranges is outside it. The dossier records that the iodine substitution particular to 2C-I falls inside the printed R4 set of that family.

Consequences if caught

Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach to 2C-I is the article 2bis ladder in the Law of 24 February 1921, reached through the same routing article as a named substance, and here the iodinated member is inside the printed family rather than named on its own. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. Annex IVA is the generic family limb, and a family result carries the same article 2bis exposure as a named entry: what differs is how the substance is proved to be listed, not what follows once it is.

If prescribed or medical

The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. 2C-I is reached through the generic family in Annex IVA group 7 rather than through a named entry, and that family is not the excluded limb, so the placement does not shut the exception out; whether a lawfully obtained medicine exists to carry is a separate question this row does not answer. No named Annex entry exists for this compound, and no Belgian medicine is recorded for it. No route specific to 2C-I was found in this dossier and none has been invented for it.

Documentation

Carry the point that this is a family result. 2C-I is not printed as its own entry: the control comes from the group 7 structure with its iodine substituent inside the printed range. The generic family at Annex IVA group 7 was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Drug laws and enforcement change and vary within a country. This is not legal advice. Always confirm with Belgium’s embassy or official drug authority before traveling; penalties can be severe, including imprisonment.